September 2022 Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model antibody atezolizumab and nab-paclitaxel has shown clinical activity in advanced TNBC with PD-L1-positive tumor-infiltrating As tumor-associated macrophages (TAMs) serve as major contributors to the immuno-suppressive tumor microenvironment We show that through proper calibration, the model captures the macrophage heterogeneity in the tumor

and inflammation, all of which are influenced by the cellular and molecular microenvironment of the tumor techniques, have been tested to reduce the malignancy and generate a harmful microenvironment for the tumor therapeutic benefits of the β-adrenergic receptor antagonist, propranolol, were described in benign tumors

Here, using colorectal cancer (CRC) as a model, we explored the gene expression of a panel of GPCRs in tumor live-imaging modalities, and displayed high efficiency when used to label complex 3D cellular systems such as tumor A2BAR as a potential pharmacological tool in CRC, using selective antagonists, finding a reduction in tumor

GPCRs in Oncology and Immunology Exploiting frequent and specific expression of PRL3 in pediatric solid tumors Published date September 21, 2023 Abstract "Phosphatase of regenerating liver 3 (PRL3) is a specific tumor However, its physiological expression in pediatric embryonal and mesenchymal tumors and its association Among 64 pediatric tumors, PRL3 was most frequently expressed in neuroblastoma (100%), rhabdomyosarcoma PRL3 was expressed in 75% of relapsed tumors and associated with shorter median event-free survival.

< GPCR News < GPCRs in Oncology and Immunology Metabolic crosstalk: Extracellular ATP and the tumor microenvironment signals inside the body, which is necessary for controlling the life activities of all cells, including tumor Its significance extends from intracellular signaling pathways to tumor regression. In the tumor microenvironment (TME), purinergic receptors such as ATP-gated ion channels P2X1-5 and G (e-ATP) , Immunosuppression , Purinergic receptors , Purinergic signaling , Therapeutic potential , Tumor

GPCRs in Oncology and Immunology G protein-coupled receptor-mediated signaling of immunomodulation in tumor Published date July 31, 2024 Abstract "G protein-coupled receptors (GPCRs) are essential contributors to tumor Here, we discuss the current understanding of the roles of GPCRs and their signaling pathways in tumor This expanded understanding of the role of GPCRs may shed light on the mechanisms underlying tumor progression Qiu, Bin Yu, Mei Ma Tags GPCRs , cancer immune checkpoints , cancer immunotherapy , immune cells , tumor